ITGR

ANALYST NOTE: ITGR (Integer Holdings Corporation) Date: 2026-06-13

(1) Structural Readiness As of the close on 2026-06-13, Integer Holdings Corporation presents a confirmed coil setup. The structure has fired, indicating active readiness.

• Conservative Entry: $100.38
• Breakout Level: The setup is confirmed; the price has cleared the entry threshold.
• Current Price: $100.86
• Extension: +0.5% vs. conservative entry.
• Volatility Context: The ATR at breakout was 2.7% (productive), and the current ATR is 2.6% (productive). This volatility profile sits within the structural quality range, suggesting the setup has the necessary momentum characteristics without being in the "extreme" volatility bucket associated with severe drawdowns. The setup is actionable.

(2) The Thesis Layer The primary secular thesis driving this setup is Biotech & GLP-1 → Platforms, Tools & CRO/CDMO. Integer Holdings is a direct beneficiary within this tier. As a global leader in outsourced medical device manufacturing (CDMO), the company provides the essential engineering, manufacturing, and supply chain infrastructure required for the development and production of complex medical devices, including those in the electrophysiology and structural heart markets which are central to the broader biotech and device innovation cycle. The company's exposure is direct, as it serves the OEMs developing these therapies.

(3) The Business Integer Holdings Corporation operates as a global contract development and manufacturing organization (CDMO) for the medical device industry.

• Operations & Segments: The company operates in a single segment deriving revenue from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets (E11, E16). It also maintains a Non-Medical segment focused on battery power systems for energy, military, and environmental sectors (E29).
• Customer Base: The business model relies on large, multinational Original Equipment Manufacturers (OEMs). As of the first quarter of 2026, three customers—Abbott Laboratories, Boston Scientific, and Medtronic—each accounted for over 10% of total sales, collectively representing 49% of total sales (E20).
• Financial Position & Backlog: As of December 31, 2025, firm backlog orders stood at approximately $675 million, with the majority expected to ship within one year (E18, E19). The company reported first-quarter 2026 sales of $440 million, up 0.5% on a reported basis and 1.3% on an organic basis (E6).
• Strategic Review: In April 2026, the Board initiated a strategic review to maximize stockholder value, considering a full range of opportunities including a sale, merger, or strategic business combination, alongside continued standalone execution (E14).
• Liquidity: Management stated that projected cash flows, available cash, and borrowings under the Revolving Credit Facility are sufficient to meet working capital, debt service, and capital expenditure requirements for the next twelve months (E9).

(4) The Archetype and Conviction Integer Holdings fits the Growth Leader archetype, though with a near-term headwind that management has explicitly quantified.

• Archetype Fit: The company is positioned as a growth leader in the CDMO space, executing a "tuck-in" acquisition strategy to add capabilities and scale (E21). However, the current growth narrative is tempered by specific product headwinds.
• Management Expectations: Management expects reported sales to be down 1% to 3% year-over-year for 2026, driven by lower adoption of three new products (E1, E8). Excluding these three products, organic sales are expected to grow 3% to 4% (E3). Management projects a return to organic sales growth 200 basis points above the market in 2027 (E5).
• Valuation & Quality: The financial spine indicates a forward consensus EPS of $6.08 for FY1 and $6.81 for FY2 (E31). The ATR metrics (2.6%–2.7%) suggest a "productive" volatility environment, avoiding the "weak" (<2.5%) or "extreme" (>8%) buckets.
• Conviction Weighting: The conviction is supported by the confirmed coil structure, the direct exposure to the high-growth CDMO theme, and a strong backlog. However, the conviction is weighed down by the explicit guidance for sales contraction in 2026 due to specific product adoption issues and the initiation of a strategic review, which introduces uncertainty regarding the company's long-term standalone trajectory versus a potential transaction.

(5) Invalidating Factors, Strengthening Factors, and Gaps

• What would Strengthen the Case: Confirmation of a strategic transaction (sale or merger) at a premium; a significant acceleration in organic growth in Q2 2026 that exceeds the flat-to-down guidance; or a successful resolution of the "three new products" adoption issue leading to an upward revision of 2027 guidance.
• What would Invalidate the Case: A material deterioration in the backlog (e.g., significant cancellations from the top three OEMs); a breach of the debt covenants (Total Net Leverage Ratio was 3.0:1.0 as of April 3, 2026) (E13); or a strategic review that concludes with a decision to liquidate assets rather than pursue a value-creating transaction.
• Gaps in Evidence: The specific timeline for the "strategic review" is not defined in the provided evidence. The specific financial impact of the "three new products" on the 2027 growth trajectory is not detailed beyond the general expectation of a return to growth. There is no evidence regarding the specific terms of the Revolving Credit Facility beyond the sufficiency statement.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Confirmed coil breakout with productive ATR; $675M firm backlog with >1 year visibility; Direct exposure to high-growth CDMO/Biotech theme. Key risks: 2026 sales guidance of -1% to -3% due to new product adoption; Concentration risk with top 3 customers (49% of sales); Strategic review outcome uncertainty. Rating boundary: This is a Buy rather than a Strong Buy because the 2026 sales contraction guidance and the active strategic review introduce near-term execution and strategic uncertainty that prevents a top-tier conviction. It is a Buy rather than a Speculative because the confirmed structural setup, strong backlog, and clear path to 2027 growth provide a defined risk/reward profile. Sizing hint: Position size should reflect the medium confidence, acknowledging the strategic review as a binary event that could alter the standalone thesis. Expected path: Management expects organic growth to return in Q4 2026 and accelerate in 2027; the strategic review may conclude with a transaction or a reaffirmation of the standalone path, likely resolving within the next 12-18 months. Expected horizon: 12 to 18 months for the strategic review to conclude and for the 2027 growth thesis to materialize. Failure mode to watch: A significant reduction in the $675M backlog or a breach of the 3.0:1.0 leverage covenant.